search
Back to results

Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation

Primary Purpose

Depression, Unipolar

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sleep deprivation
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Depression, Unipolar

Eligibility Criteria

21 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Current depression as assessed on the HDRS-17 (for depressed group only)
  • Body mass index within 15% of normal
  • Stable, normally-timed sleep-wake cycle defined by: a. Habitual nocturnal sleep duration between 6h and 9h. b. Habitual morning awakening between 0600h and 0800h.
  • Able to comprehend English, as all questionnaires are in this language
  • Ability to provide informed consent

Exclusion Criteria:

  • Shift work, transmeridian travel or irregular sleep/wake routine in past 60 days
  • A sleep disorder other than insomnia
  • History of bipolar disorder, delirium, dementia, amnestic disorder, schizophrenia and other psychotic disorders
  • No history of depression for the control group.
  • Alcohol or drug abuse in the past year
  • A current smoker.
  • Any acute or chronic, debilitating medical conditions, epilepsy, or thyroid disease.
  • Metallic implants, pacemakers or tattoos, or history of working in metal workshops.
  • Claustrophobic, or intolerant of the scanner environment.
  • For women, pregnancy will exclude participation.

Sites / Locations

  • University of Pennsylvania

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Sleep deprivation

Arm Description

36-hours of total sleep deprivation

Outcomes

Primary Outcome Measures

Change in HAMD-NOW scores
Total score on a modified Hamilton Depression Inventory that assesses mood symptoms in the moment.

Secondary Outcome Measures

Change in neuroimaging
Resting-state brain functional connectivity on fMRI

Full Information

First Posted
May 24, 2017
Last Updated
March 24, 2020
Sponsor
University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT03169543
Brief Title
Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation
Official Title
Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
April 1, 2016 (Actual)
Primary Completion Date
February 28, 2020 (Actual)
Study Completion Date
February 28, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
From 40 to 60% of patients with depression experience a rapid and significant improvement of mood with one night of sleep deprivation (SD). The neural mechanisms underlying this effect have not been elucidated. Recent advances in functional neuroimaging have provided new opportunities to investigate state changes in regional brain function, along with a better understanding of the neural networks affected by depression and SD. Here we propose to study a group of N=48 antidepressant-free male and female patients with current depression symptom and N=12 healthy controls with no history of mood disorders before and after SD to provide mechanistic insight into the neural substrates underlying the antidepressant effects of SD. We hypothesize that SD-induced concurrent functional activity and connectivity changes in multiple brain networks related to different depressive symptom dimensions including emotion regulation, attention, arousal, self-referential, and reward processing will underlie the rapid and transient antidepressant effects of SD. Using an ABA design, multimodal brain imaging along with more traditional electroencephalographic (EEG) and neurobehavioral testing data will be acquired at baseline after normal sleep, during one night of total SD, and after one night of recovery sleep using a 5-day in laboratory protocol during which subjects will be continuously monitored by trained staff.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Unipolar

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sleep deprivation
Arm Type
Experimental
Arm Description
36-hours of total sleep deprivation
Intervention Type
Behavioral
Intervention Name(s)
Sleep deprivation
Intervention Description
36-hours total sleep deprivation
Primary Outcome Measure Information:
Title
Change in HAMD-NOW scores
Description
Total score on a modified Hamilton Depression Inventory that assesses mood symptoms in the moment.
Time Frame
Each morning for 4 days
Secondary Outcome Measure Information:
Title
Change in neuroimaging
Description
Resting-state brain functional connectivity on fMRI
Time Frame
Each morning for 3 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Current depression as assessed on the HDRS-17 (for depressed group only) Body mass index within 15% of normal Stable, normally-timed sleep-wake cycle defined by: a. Habitual nocturnal sleep duration between 6h and 9h. b. Habitual morning awakening between 0600h and 0800h. Able to comprehend English, as all questionnaires are in this language Ability to provide informed consent Exclusion Criteria: Shift work, transmeridian travel or irregular sleep/wake routine in past 60 days A sleep disorder other than insomnia History of bipolar disorder, delirium, dementia, amnestic disorder, schizophrenia and other psychotic disorders No history of depression for the control group. Alcohol or drug abuse in the past year A current smoker. Any acute or chronic, debilitating medical conditions, epilepsy, or thyroid disease. Metallic implants, pacemakers or tattoos, or history of working in metal workshops. Claustrophobic, or intolerant of the scanner environment. For women, pregnancy will exclude participation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip Gehrman, PhD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation

We'll reach out to this number within 24 hrs